Is a single COVID-19 vaccine dose enough in convalescents ?

References

• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. medrXiv [Preprint]. 2020;384:403–16.
   Google Scholar
• Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Israeli healthcare workers, December-January 2020. medrXiv [Preprint]. 2021. doi:10.1101/2021.01.27.21250567.
   Google Scholar
• Krammer F, Srivastava K, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medrXiv [Preprint]. 2021. doi:10.1101/2021.01.29.21250653.
   Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Figueiredo JC, Van Eyk J, Braun J, Cheng S, Sobhani K. Prior COVID-19 infection and antibody response to single versus double dose mRNA SARS-CoV-2 vaccination. medrXiv [Preprint]. 2021. doi:10.1101/2021.02.23.21252230.
   Google Scholar
• Narasimhan M, Mahimainathan L, Araj E, Clark AE, Markantonis J, Green A, Xu J, SoRelle JA, Alexis C, Fankhauser K, Parikh H. Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups. medrXiv [Preprint]. 2021. doi:10.1101/2021.02.17.21251940.
   Google Scholar
• Velasco M, Galan MI, Casas ML, Perez-Fernandez E, Gonzalez-Pinyeiro B, Castilla V, Guijarro C. Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.08.21253065.
   Google Scholar
• Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, Maggiolo F. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.09.21253203.
   Google Scholar
• Kelsen SG, Braverman A, Patel P, Aksoy MO, Hayman J, Rajput C, Ruggieri MR, Gentile N. Heightened COVID-19 Vaccine Response Following SARS-CoV-2 Infection. medRxiv [Preprint]. 2021. doi:10.1101/2021.03.18.21253845.
   Google Scholar
• Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussieres G, Brassard N, Laumaea A, Vézina D, Prevost J, Anand SP. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.18.435972.
   Google Scholar
• Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, Gouma S, Kuri-Cervantes L, Meng W, Adamski S, Baxter AE. Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.03.21252872.
   Google Scholar
• Samanovic-Golden MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz G, Ali M, Koralov SP, Mulligan MJ. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medrXiv [Preprint]. 2021. doi:10.1101/2021.02.07.21251311.
   Google Scholar
• Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA, Zuo M, Woodard W. Prothrombotic antiphospholipid antibodies in COVID-19. medrXiv [Preprint]. 2020. doi:10.1101/2020.06.15.20131607.
   Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–23. doi:10.1517/17425247.2012.720969.
   PubMed Web of Science ®Google Scholar
• Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther. 2005;312:1020–26. doi:10.1124/jpet.104.078113.
   PubMed Web of Science ®Google Scholar
• Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M. A cautionary note on recall vaccination in ex-COVID-19 subjects. medrXiv [Preprint]. 2021. doi:10.1101/2021.02.01.21250923.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Czartoski J, Wan Y-H, Homad L, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy A, Feng J. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medrXiv [Preprint]. 2021. doi:10.1101/2021.02.05.21251182.
   Google Scholar
• Trinite B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarres-Freixas F, Ortiz R, Vergara-Alert J, Segales J, Guallar V, Lepore A. Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.05.433800.
   Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, Simmons R, Cottrell S, Robertson R, O’Doherty M, Brown K. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.01.21252652.
   Google Scholar
• Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;14:1467. doi:10.1001/jama.2021.3341.
   PubMed Web of Science ®Google Scholar
• Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Saber R, Vaught LA, Reiser NL, Richard TD, Mustanski B, McNally EM, McDade TW. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.04.21252913.
   Google Scholar
• Grupel D, Gazit S, Schreiber L, Nadler V, Wolf T, Lazar R, Supino-Rosin L, Perez G, Peretz A, Tov AB, Mizrahi-Reuveni M. et al. Kinetics of SARS-CoV-2 anti-s IgG after BNT162b2 vaccination. medrXiv [Preprint]. 2021; doi:10.1101/2021.03.03.21252844.
   Google Scholar
• Müller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, Ostermann PN. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. medrXiv [Preprint]. 2021. doi:10.1101/2021.03.03.21251066.
   Google Scholar
• Ayoub HH, Chemaitelly H, Makhoul M, Kanaani ZA, Kuwari EA, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: mathematical modeling analyses. medrXiv [Preprint]. 2021. doi:10.1101/2021.01.10.21249382.
   Google Scholar
• WHO. SAGE roadmap for prioritizing uses of COVID19 vaccines in the context of limited supply. Version 1.1., 2020.
   Google Scholar